PDS Biotechnology (PDSB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Proxy statement filed for annual meeting, including voting on key corporate matters.
Voting matters and shareholder proposals
Shareholders are asked to vote on proposals as outlined in the proxy statement.
Shareholder rights and capital structure
No filing fee required, indicating no material change to capital structure or issuance.
Partial view of Summaries dataset, powered by Quartr API
Latest events from PDS Biotechnology
- FDA-aligned Phase 3 trial of Versamune HPV doublet in HPV16+ cancer starts Q4 2024.PDSB
Status Update2 Feb 2026 - Q3 net loss narrowed to $10.7M, cash at $49.8M, but going concern risk persists.PDSBQ3 202414 Jan 2026
- Phase III trial for Versamune HPV launched; 2024 net loss narrowed, cash boosted by new offering.PDSBQ4 202426 Dec 2025
- Versamune HPV plus Keytruda delivers 30-month median survival in HPV-16 head and neck cancer.PDSBLife Sciences Virtual Investor Conference26 Dec 2025
- Up to $200 million in securities offered to fund immunotherapy pipeline amid ongoing losses and risk.PDSBRegistration Filing16 Dec 2025
- Registering 9.8M shares for resale after $20M private placement to fund immunotherapy R&D.PDSBRegistration Filing16 Dec 2025
- Annual meeting to vote on directors, equity plan, auditor, and executive pay, with ESG focus.PDSBProxy Filing1 Dec 2025
- Proposal 2 would raise equity plan overhang from 15% to 20% if approved by majority vote.PDSBProxy Filing1 Dec 2025
- Equity plan amendment would raise overhang to 20%, clarifying dilution and voting impacts.PDSBProxy Filing1 Dec 2025